Introduction to Antipsychotics and Dementia The management of behavioral and psychological symptoms of dementia (BPSD) represents one of the most challenging aspects of geriatric psychiatry and neurology. Dementia, characterized by progressive cognitive decline, often leads to non-cognitive symptoms such as agitation, aggression, psychosis, and sleep disturbances, collectively known as BPSD. While pharmacological interventions are frequently […]
Introduction to Attitudes toward Antipsychotics Attitudes toward antipsychotic medications represent a complex and multifaceted domain within psychiatric care, encompassing the beliefs, emotional responses, and evaluative judgments held by patients, clinicians, families, and the wider public regarding these pharmacological interventions. These attitudes are not merely passive opinions; they are powerful psychological constructs that fundamentally influence treatment […]
Introduction to Second-Generation Antipsychotics (SGAs) The introduction of Second-Generation Antipsychotics (SGAs), often referred to as atypical antipsychotics, marked a significant paradigm shift in the pharmacological management of severe mental illnesses, primarily schizophrenia, bipolar disorder, and treatment-resistant depression. Unlike their predecessors, the First-Generation Antipsychotics (FGAs), SGAs were initially heralded for their reduced propensity to induce extrapyramidal […]